Canada

Uplizna now approved in Canada to treat adults with NMOSD

Health Canada has approved Uplizna (inebilizumab-cdon) to treat adults in the country with neuromyelitis optica spectrum disorder (NMOSD) who test positive for disease-driving anti-aquaporin-4 (AQP4) antibodies. The decision adds Canada to the list of nations where the medication is now available. The intravenous or into-the-vein infusion, developed by…

Ultomiris now approved in Canada for AQP4-positive NMOSD adults

Ultomiris (ravulizumab) is now approved in Canada to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). According to a press release from Alexion Canada, which will market Ultomiris in the country, it’s the “first and only” long-acting therapy…

Why Lifting COVID-19 Restrictions Has Me Worried

I have a theory: I’m convinced you can scream (almost) anything at a baseball game. The more obscure the cheer, the greater it is. “You call that peanut butter?!” “Turn ’em upside down!” “Let’s go, captain! Take ’em out to sea!” (This one is way more fun when said in…

Embracing Science for My Own Survival

We cannot separate science from life. Trust me, I’ve tried. Like most young people, I once thought of myself as invincible. So I was absolutely stunned when I was diagnosed with neuromyelitis optica (NMO) at the age of 24. With the diagnosis, my world came crumbling down. Yet while…